(Q51062307)

28 March 2018

review article

1 reference

title

A robustness-based approach to systems-oriented drug design. (English)

1 reference

28 March 2018

author name string

Hiroaki Kitano

series ordinal

1

1 reference

28 March 2018

publication date

23 February 2007

1 reference

28 March 2018

Nature Reviews Drug Discovery

published in

1 reference

28 March 2018

volume

6

1 reference

28 March 2018

page(s)

202-210

1 reference

28 March 2018

issue

3

1 reference

28 March 2018

https://scigraph.springernature.com/pub.10.1038/nrd2195

exact match

0 references

cites work

Drug research: myths, hype and reality

1 reference

Modern biomedical research: an internally self-consistent universe with little contact with medical reality?

31 March 2020

1 reference

Can cell systems biology rescue drug discovery?

31 March 2020

1 reference

Systems biology in drug discovery

31 March 2020

1 reference

The impact of systems approaches on biological problems in drug discovery

31 March 2020

1 reference

Innovation: Rescuing drug discovery: in vivo systems pathology and systems pharmacology

31 March 2020

1 reference

Multicomponent therapeutics for networked systems

31 March 2020

1 reference

The concept of synthetic lethality in the context of anticancer therapy

31 March 2020

1 reference

The challenges of modeling mammalian biocomplexity

31 March 2020

1 reference

Metabolite profiling: from diagnostics to systems biology

31 March 2020

1 reference

Understanding 'Global' Systems Biology: Metabonomics and the Continuum of Metabolism

31 March 2020

1 reference

Metabolic footprinting and systems biology: the medium is the message

31 March 2020

1 reference

31 March 2020

Biological robustness

1 reference

Robustness of cellular functions

31 March 2020

1 reference

Reverse engineering of biological complexity

31 March 2020

1 reference

Bow ties, metabolism and disease

31 March 2020

1 reference

Highly Optimized Tolerance: Robustness and Design in Complex Systems

31 March 2020

1 reference

Complexity and robustness

31 March 2020

1 reference

Self-perpetuating states in signal transduction: positive feedback, double-negative feedback and bistability

31 March 2020

1 reference

Robustness of the bistable behavior of a biological signaling feedback loop

31 March 2020

1 reference

Between genotype and phenotype: protein chaperones and evolvability

31 March 2020

1 reference

Decomposition of metabolic network into functional modules based on the global connectivity structure of reaction graph

31 March 2020

1 reference

Robustness trade-offs and host-microbial symbiosis in the immune system

31 March 2020

1 reference

A comprehensive map of the toll-like receptor signaling network

31 March 2020

1 reference

The "robust yet fragile" nature of the Internet

31 March 2020

1 reference

The Byzantine Generals Problem

31 March 2020

1 reference

Metabolic syndrome and robustness tradeoffs

31 March 2020

1 reference

Cancer as a robust system: implications for anticancer therapy

31 March 2020

1 reference

Cancer robustness: Tumour tactics

31 March 2020

1 reference

Lysogenic conversion by a filamentous phage encoding cholera toxin

31 March 2020

1 reference

Small-molecule inhibitor of Vibrio cholerae virulence and intestinal colonization

31 March 2020

1 reference

Evolution and spread of antibiotic resistance

31 March 2020

1 reference

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia

31 March 2020

1 reference

Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining

31 March 2020

1 reference

Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome

31 March 2020

1 reference

Induction of a chronic myelogenous leukemia-like syndrome in mice with v-abl and BCR/ABL.

31 March 2020

1 reference

Acute leukaemia in bcr/abl transgenic mice

31 March 2020

1 reference

Tyrosine kinase activity and transformation potency of bcr-abl oncogene products.

31 March 2020

1 reference

Strategies to overcome resistance to targeted protein kinase inhibitors

31 March 2020

1 reference

Lovastatin and extended-release niacin combination product: the first drug combination for the management of hyperlipidemia

31 March 2020

1 reference

Comparison of once-daily, niacin extended-release/lovastatin with standard doses of atorvastatin and simvastatin (the ADvicor Versus Other Cholesterol-Modulating Agents Trial Evaluation [ADVOCATE]).

31 March 2020

1 reference

Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy

31 March 2020

1 reference

Systematic discovery of multicomponent therapeutics

31 March 2020

1 reference

The efficiency of multi-target drugs: the network approach might help drug design

31 March 2020

1 reference

Multiple weak hits confuse complex systems: a transcriptional regulatory network as an example.

31 March 2020

1 reference

Traditional Chinese medicine: an approach to scientific proof and clinical validation

31 March 2020

1 reference

Metabolomics in the context of systems biology: bridging traditional Chinese medicine and molecular pharmacology

31 March 2020

1 reference

Scale-rich metabolic networks

31 March 2020

1 reference

Classification and diagnostic prediction of cancers using gene expression profiling and artificial neural networks

31 March 2020

1 reference

Zipf's law in importance of genes for cancer classification using microarray data.

31 March 2020

1 reference

Oxaliplatin, a potent inhibitor of survivin, enhances paclitaxel-induced apoptosis and mitotic catastrophe in colon cancer cells

31 March 2020

1 reference

Targeting the cell cycle: a new approach to cancer therapy

31 March 2020

1 reference

A phase I clinical trial of the sequential combination of irinotecan followed by flavopiridol

31 March 2020

1 reference

31 March 2020

1 reference

Circadian chronotherapy for human cancers

31 March 2020

1 reference

Deregulated expression of the PER1, PER2 and PER3 genes in breast cancers.

31 March 2020

1 reference

The circadian gene per1 plays an important role in cell growth and DNA damage control in human cancer cells

31 March 2020

1 reference

In vivo robustness analysis of cell division cycle genes in Saccharomyces cerevisiae

31 March 2020

1 reference

31 March 2020

1 reference

Bifurcation analysis of a model of mitotic control in frog eggs

31 March 2020

1 reference

Epidermal growth factor receptor (EGFR) and EGFR mutations, function and possible role in clinical trials

31 March 2020

1 reference

Epidermal growth factor-related peptides and their receptors in human malignancies

31 March 2020

1 reference

Prediction of sensitivity of advanced non-small cell lung cancers to gefitinib (Iressa, ZD1839).

31 March 2020

1 reference

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

31 March 2020

1 reference

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

31 March 2020

1 reference

United States Food and Drug Administration Drug Approval summary: Gefitinib (ZD1839; Iressa) tablets

31 March 2020

1 reference

Uncoupling between epidermal growth factor receptor and downstream signals defines resistance to the antiproliferative effect of Gefitinib in bladder cancer cells

31 March 2020

1 reference

EGFR mutation and resistance of non-small-cell lung cancer to gefitinib

31 March 2020

1 reference

Humanization of an anti-p185HER2 antibody for human cancer therapy

31 March 2020

1 reference

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

31 March 2020

1 reference

Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease

31 March 2020

1 reference

Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer

31 March 2020

1 reference

Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin).

31 March 2020

1 reference

PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients.

31 March 2020

1 reference

The coxibs, selective inhibitors of cyclooxygenase-2.

31 March 2020

1 reference

Characterization of Prostaglandin G/H Synthase 1 and 2 in rat, dog, monkey, and human gastrointestinal tracts

31 March 2020

1 reference

Prostaglandin G/H synthase isoenzyme 2 expression in fibroblasts: regulation by dexamethasone, mitogens, and oncogenes

31 March 2020

1 reference

The development of COX2 inhibitors

31 March 2020

1 reference

Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial

31 March 2020

1 reference

Coxibs and heart disease: what we have learned and what else we need to know

31 March 2020

1 reference

New targeted approaches in chronic myeloid leukemia

31 March 2020

1 reference

31 March 2020

Heat shock protein 90.

1 reference

BCR-ABL point mutants isolated from patients with imatinib mesylate-resistant chronic myeloid leukemia remain sensitive to inhibitors of the BCR-ABL chaperone heat shock protein 90.

31 March 2020

1 reference

Hsp90 inhibitor 17-AAG reduces ErbB2 levels and inhibits proliferation of the trastuzumab resistant breast tumor cell line JIMT-1.

31 March 2020

1 reference

Epidermal growth factor receptors harboring kinase domain mutations associate with the heat shock protein 90 chaperone and are destabilized following exposure to geldanamycins

31 March 2020

1 reference

Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT)

31 March 2020

1 reference

Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3'-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase

31 March 2020

1 reference

Cooperative cell-growth inhibition by combination treatment with ZD1839 (Iressa) and trastuzumab (Herceptin) in non-small-cell lung cancer.

31 March 2020

1 reference

A recent illustration of some essentials of circadian chronotherapy study design

31 March 2020

1 reference

31 March 2020

Chronotherapy for cancer

1 reference

Circadian-system alterations during cancer processes: a review

31 March 2020

1 reference

Randomised multicentre trial of chronotherapy with oxaliplatin, fluorouracil, and folinic acid in metastatic colorectal cancer. International Organization for Cancer Chronotherapy

31 March 2020

1 reference

Maintenance chemotherapy for childhood acute lymphoblastic leukaemia: better in the evening

31 March 2020

1 reference

31 March 2020

Identifiers

DOI

10.1038/NRD2195

1 reference

28 March 2018

PubMed ID

17318209

1 reference

28 March 2018